NYSE · PG
The Procter & Gamble Company
$160.59+$2.33 (+1.47%)
The Procter & Gamble Company’s quoted price sits in the upper half of its reported 52-week range, 3.98% below the high.
Loading market information…
ASX · AN1.AX · AUD
Stock price, earnings
Quote as of Oct 28, 2026, 11:04 PM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Anagenics Limited’s quoted price sits in the lower half of its reported 52-week range, 44.44% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Anagenics Limited’s next earnings report is currently expected on Mar 3, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Anagenics Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Anagenics Limited engages in the health wellness and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name. It also imports and distributes skin care and wellbeing products to spas, clinics, salons, retail stores, and online in Australia, New Zealand, and the Pacific Islands. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:20 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$160.59+$2.33 (+1.47%)
The Procter & Gamble Company’s quoted price sits in the upper half of its reported 52-week range, 3.98% below the high.
£49.00+£1.29 (+2.69%)
Unilever PLC’s quoted price sits in the upper half of its reported 52-week range, 11.59% below the high.
£54.22+£1.40 (+2.65%)
Reckitt Benckiser Group plc’s quoted price sits in the upper half of its reported 52-week range, 16.88% below the high.
$108.81-$0.50 (-0.46%)
The Estée Lauder Companies Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.55% below the high.
$5.08-$0.13 (-2.5%)
Newell Brands Inc.’s quoted price sits in the lower half of its reported 52-week range, 28.75% below the high.
A$1.03-A$0.03 (-2.38%)
BLS Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 21.15% below the high.
A$0.27+A$0.01 (+1.92%)
Alterity Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 66.24% below the high.
A$0.08-A$0.01 (-5.62%)
Amplia Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 69.45% below the high.
